The Revise on the Dangers along with Perils of Forensic Anthropology, Portion We: Human being Stays.

86 × 106 and 1.04 × 105 A W-1 , detectivity (D*) of above 1.49 × 1018 and 5.28 × 1016 Jones under 370 nm light illumination, respectively. It indicates the great potential of 1,6-DTEP and 2,7-DTEP-based phototransistors for organic UV-photodetector applications and also provides a new design strategy to develop series of better performance UV photoelectric organic materials for related research in organic optoelectronics. © 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.Acute gout flares account for a substantial number of visits to the emergency department (ED). Treatment of the acute gout flare in the ED was the subject of an interesting article by Dalal DS et al.. The authors reported that 28.3% of the 456 patients included in the study received an opioid at discharge. Furthermore, 80% of the opioid prescriptions were new, indicating a large proportion of patients without previous exposure to an opioid were now exposed. We reported on the diagnosis and treatment of acute gout flares in a large series of 541 consecutive ED visits over a 7-year period (3). This article is protected by copyright. All rights reserved.Metallic lithium is the most competitive anode material for next-generation lithium (Li)-ion batteries. However, one of its major issues is Li dendrite growth and detachment, which not only causes safety issues, but also continuously consumes electrolyte and Li, leading to low coulombic efficiency (CE) and short cycle life for Li metal batteries. Herein, the Li dendrite growth of metallic lithium anode is suppressed by forming a lithium fluoride (LiF)-enriched solid electrolyte interphase (SEI) through the lithiation of surface-fluorinated mesocarbon microbeads (MCMB-F) anodes. The robust LiF-enriched SEI with high interfacial energy to Li metal effectively promotes planar growth of Li metal on the Li surface and meanwhile prevents its vertical penetration into the LiF-enriched SEI from forming Li dendrites. At a discharge capacity of 1.2 mAh cm-2 , a high CE of >99.2% for Li plating/stripping in FEC-based electrolyte is achieved within 25 cycles. Coupling the pre-lithiated MCMB-F (Li@MCMB-F) anode with a commercial LiFePO4 cathode at the positive/negative (P/N) capacity ratio of 11, the LiFePO4 //Li@MCMB-F cells can be charged/discharged at a high areal capacity of 2.4 mAh cm-2 for 110 times at a negligible capacity decay of 0.01% per cycle. © 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.Recent studies have shown that multidrug resistance may be induced by the high stemness of cancer cells. In previous study, we found bufalin could reverse multidrug resistance and inhibit cancer cell stemness in colorectal cancer, but the relationship between them was unclear. Here we identified over-expressing CD133 increases levels of Akt/NF-κB signaling mediators and MDR1, while increasing cell chemoresistance. Furthermore, bufalin reverses colorectal cancer multidrug resistance by regulating cancer cell stemness via the CD133/NF-κB/MDR1 pathway in vitro and in vivo. Taken together, our results suggest that bufalin could be developed as a novel two-pronged drug that targets CD133 and MDR1 to eradicate MDR cells and could ultimately be combined with conventional chemotherapeutic agents to improve treatment outcomes for patients with CRC. This article is protected by copyright. All rights reserved.The pharmacokinetic properties of drugs are affected in several ways by interactions with microbiota. FB232 The aim of this study was to investigate the effects of oral vancomycin on the gut microbiota and, consequently, on the pharmacokinetics of simvastatin. An open-label, single arm, sequential crossover study was conducted in six healthy Korean male subjects. After 6 days on a control diet, simvastatin 40 mg was orally administered to the subjects before and after 1 week of oral vancomycin treatment. Blood samples for pharmacokinetic analysis and fecal samples for metagenomic and metabolomic analyses were collected. After vancomycin treatment, the richness of microbiota considerably decreased, and the composition was altered. In particular, the relative abundance of Bacteroidetes decreased, while that of Proteobacteria increased. In addition, changes in fecal metabolites, including D-glucuronic acid, were observed. However, systemic exposure of simvastatin was not changed while that of hydroxysimvastatin showed a tendency to increase. The relationship between the change of pharmacokinetics of simvastatin and the change of gut microbiota and fecal metabolites were not clearly observed. © 2020 The Authors. Clinical and Translational Science published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics.We would like to thank the editors for providing us an opportunity to further the discussion regarding opioid use for management of acute gout and Dr. Schlesinger and colleagues for highlighting yet another study describing the burden of opioid prescription for gout management. As appropriately pointed out, opioids do not reduce the inflammation of an acute gout attack and conventional anti-inflammatories like colchicine, non-steroidal anti-inflammatory drugs (NSAIDs), and steroids can substantially reduce pain within the first 24 hours of administration. This article is protected by copyright. All rights reserved.Clinical studies, especially randomized controlled trials, are essential for generating evidence for clinical practice. However, generalizability is a long-standing concern when applying trial results to real-world patients. Generalizability assessment is thus important, nevertheless, not consistently practiced. We performed a systematic review to understand the practice of generalizability assessment. We identified 187 relevant papers and systematically organized these studies in a taxonomy with three dimensions (1) data availability (i.e., before or after trial [a priori vs a posteriori generalizability]), (2) result outputs (i.e., score vs non-score), and (3) populations of interest. We further reported disease areas, underrepresented subgroups, and types of data used to profile target populations. We observed an increasing trend of generalizability assessments, but less than 30% of studies reported positive generalizability results. As a priori generalizability can be assessed using only study design information (primarily eligibility criteria), it gives investigators a golden opportunity to adjust the study design before the trial starts.FB232